Figure 4. Prognostic impact of total CD31 expression on overall survival (OS), progression-free survival (PFS), local progression-free survival (LPFS) and distant metastases free survival (DMFS) in patients with tumors of moderate stroma density, as indicated.

Analysis was based on the dichotomized percentage of CD31 surface area expression in resected patient samples (cut-off according to median value of surface area expression percentage).